Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North …
WT Atchley, C Alvarez, S Saxena-Beem, TA Schwartz… - Chest, 2021 - Elsevier
Background Immune checkpoint inhibitors (ICIs) are standard treatments for advanced non-
small cell lung cancer and have expanded use in small cell lung cancer. Although generally
better tolerated than traditional chemotherapy, immune-related adverse events, such as
immune checkpoint inhibitor-related pneumonitis (ICI-P), remain poorly understood toxicities
that limit ICI treatment and can result in considerable morbidity. In this retrospective case-
control study, we assessed a lung cancer cohort to identify ICI-P risk factors. Research …
small cell lung cancer and have expanded use in small cell lung cancer. Although generally
better tolerated than traditional chemotherapy, immune-related adverse events, such as
immune checkpoint inhibitor-related pneumonitis (ICI-P), remain poorly understood toxicities
that limit ICI treatment and can result in considerable morbidity. In this retrospective case-
control study, we assessed a lung cancer cohort to identify ICI-P risk factors. Research …